Skip to content
Tempe Knee Help
A local field guide to claims, comparators, and practical choices

Tempe Knee Help

Common questions about a sore knee

A stiff knee can raise more questions than a short visit has time to answer. These replies cover what usually matters first.

They can't tell what's wrong without an exam. Read them before talking with a doctor who can examine your knee.

A few notes can make your knee visit more useful

Think about your soreness, health, and hardest daily task while reading each answer. Care for mild wear may not fit a knee that catches or buckles.

Write down your medicines, old X-ray findings, and questions about cost. If heat, redness, or sudden weakness appears, seek care promptly.

What does regenerative medicine mean for a sore knee?

Regenerative medicine is a broad name for care meant to help the body repair damaged tissue. For knees, the name doesn't mean a worn joint will grow back, and clinics may use very different kinds of care.

Can care made from your blood ease knee soreness?

Some people move better or feel less sore after blood-based care, but research results are mixed. It can't promise to rebuild the smooth covering over the bones inside your knee.

Can a procedure seem helpful because you expect relief?

PRP means part of your blood is spun so it holds more platelets, the small pieces that help blood clot. One careful study found it didn't ease soreness more than plain salt water, while other research found some help.

How much does blood-based knee care cost?

There isn't one price because clinics may prepare the blood differently or plan a different number of visits. Ask for the full amount in writing, including supplies, later visits, and your cost if the first care doesn't help.

Does being bone on bone mean I waited too long?

Severe wear may make surgery worth discussing, but an X-ray alone can't decide what you need. The exam must also consider your soreness, balance, health, and whether daily tasks have become too hard.

What questions should I ask a clinic?

Ask what may be causing the soreness, what the proposed care is made from, and how long relief may last. You'll also want the full cost, recovery time, risks, and the next choice if it doesn't help.

Sources

  1. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

    Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

  2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

    Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

  3. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it.

    Sadeghirad B, et al. — Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.. Osteoarthritis and cartilage, 2024. DOI: 10.1016/j.joca.2024.04.021.

  4. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

    US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

  5. A Level-1a systematic review of 87 randomized PRP-for-knee-OA trials (7,925 patients, 8,118 knees) scored them against the 23-item MIBO reporting checklist. The overall MIBO score was 72%, 71% of studies scored below 80%, and reporting was worst on exactly the items that define the product: whole-blood characteristics (20%), platelet recovery rate (22%), PRP analysis (30%), PRP activation (47%). Adherence did not improve after MIBO was published. Much of the PRP literature does not say what was actually injected.

    Nakagawa HF, et al. — Systematic Review of Randomized Controlled Trials Evaluating the Use of Platelet-Rich Plasma for Knee Osteoarthritis: Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics.. The American journal of sports medicine, 2025. DOI: 10.1177/03635465241249996.

  6. A JBJS systematic review screened 420 papers on intra-articular cellular therapy for knee OA and focal cartilage defects and found only SIX at Level III evidence or higher (4 Level II, 2 Level III), covering 300 knees, with wide variation in cell source, cell characterisation, adjuvant therapy and outcome assessment - meaning no consensus exists on indications, cell sources, preparation or delivery. Two products called 'stem cell therapy' at two clinics may share almost nothing.

    Chahla J, et al. — Intra-Articular Cellular Therapy for Osteoarthritis and Focal Cartilage Defects of the Knee: A Systematic Review of the Literature and Study Quality Analysis.. The Journal of bone and joint surgery. American volume, 2016. DOI: 10.2106/JBJS.15.01495.

A first talk can clear up your choices

The first clinic talk can cover the exam, earlier care, and the daily tasks you miss. Take questions about time, price, recovery, and what happens if the proposed care doesn't help.

Book a free consultation